Exciting New Antibiotic Studies

Both In Lab & Humans

Antibiotics Found To Be More Effective

Part 1- In the past few years a series of studies have been done in labs that gives us an idea of what the best drugs are for treating/killing ALL forms of Lyme disease.

The work continues to built on the work of others before them, including Dr. Alan MacDonald, Eva Sapi, Ph.D., Brorson & Brorson and some additional well respected researchers.

The latest studies tested a long list of FDA approved drugs already on the market that included some currently used for treating cancer and other diseases. They also performed studies on various essential oils, spices, etc. to find out which ones, if any, might be effective in killing various forms of the Lyme bacteria.

The series of lab studies mentioned above can be found below under the heading Part 1 Studies. If you click the title you can read the abstract and/or full study linked there.

Part 2-Human Studies- Some of the antibiotics that tested successfully in the lab (Part 1 Studies) were then prescribed singly or in combination by long-time treating doctors in clinical studies of Lyme patients. Some of those studies can be found below under the heading Part 2 Human Studies. Other studies are in progress.

I share this information for several reasons, but it also comes with a warning.

Part 1 studies were performed in a lab and were not used in humans. More work needs to be done before successful protocols can be tested and established. Thankfully, we have a few researchers actually looking for a cure.

Part 2 studies were only recently performed by very experienced Lyme treating doctors using Lyme patients. More work needs to be done before all of the kinks can be worked out, but the results are looking promising.

The main reason I share this information is to let those who are suffering know that there is hope and we are finally moving towards finding a cure!

Thanks so much to the lab researchers and physicians named below on their studies. Keep up the fantastic work!

Part 1- Lab Studies

Essential Oils with High Activity against Stationary Phase Bartonella henselae

by Xiao Ma, Wanliang Shi and Ying Zhang ^*

Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA

Author to whom correspondence should be addressed.

Antibiotics 2019, 8(4), 246; https://doi.org/10.3390/antibiotics8040246

Link to Study

https://www.mdpi.com/2079-6382/8/4/246

Article- These 10 essential oils can kill persistent Lyme disease

https://www.medicalnewstoday.com/articles/323881.php#1

~~

Stationary phase persister/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, Post-treatment Lyme Disease Syndrome (PTLDS), and treatment failure.

Feng J, Li T, Yee R, Yuan Y, Bai C, Cai M, Shi W, Embers M, Brayton C, Saeki H, Gabrielson K, Zhang Y.

Discov Med. 2019 Mar;27(148):125-138.

~~

Identification of Essential Oils with Strong Activity against Stationary Phase Borrelia burgdorferi.

Feng J, Shi W, Miklossy J, Tauxe GM, McMeniman CJ, Zhang Y.

Antibiotics (Basel). 2018 Oct 16;7(4). pii: E89. doi: 10.3390/antibiotics7040089.

~~

Selective Essential Oils from Spice or Culinary Herbs Have High Activity against Stationary Phase and Biofilm Borrelia burgdorferi.

Feng J, Zhang S, Shi W, Zubcevik N, Miklossy J, Zhang Y.

Front Med (Lausanne). 2017 Oct 11;4:169. doi: 10.3389/fmed.2017.00169. eCollection 2017.

~~

Activity of Sulfa Drugs and Their Combinations against Stationary Phase B. burgdorferi In Vitro.

Feng J, Zhang S, Shi W, Zhang Y.

Antibiotics (Basel). 2017 Mar 22;6(1). pii: E10. doi: 10.3390/antibiotics6010010.

~~

Ceftriaxone Pulse Dosing Fails to Eradicate Biofilm-Like Microcolony B. burgdorferiPersisters Which Are Sterilized by Daptomycin/ Doxycycline/Cefuroxime without Pulse Dosing.

Feng J, Zhang S, Shi W, Zhang Y.

Front Microbiol. 2016 Nov 4;7:1744. eCollection 2016.

~~

A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library.

Feng J, Shi W, Zhang S, Sullivan D, Auwaerter PG, Zhang Y.

Front Microbiol. 2016 May 23;7:743. doi: 10.3389/fmicb.2016.00743. eCollection 2016.

~~

Eradication of Biofilm-Like Microcolony Structures of Borrelia burgdorferi by Daunomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime.

Feng J, Weitner M, Shi W, Zhang S, Zhang Y.

Front Microbiol. 2016 Feb 10;7:62. doi: 10.3389/fmicb.2016.00062. eCollection 2016.

~~

Persister mechanisms in Borrelia burgdorferi: implications for improved intervention.

Feng J, Shi W, Zhang S, Zhang Y.

Emerg Microbes Infect. 2015 Aug;4(8):e51. doi: 10.1038/emi.2015.51. Epub 2015 Aug 19. No abstract available. Erratum in: Emerg Microbes Infect. 2015;4:e56.

~~

Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library.

Feng J, Wang T, Shi W, Zhang S, Sullivan D, Auwaerter PG, Zhang Y.

Emerg Microbes Infect. 2014 Jul;3(7):e49. doi: 10.1038/emi.2014.53. Epub 2014 Jul 2.

~~

Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline.

Feng J, Auwaerter PG, Zhang Y.

PLoS One. 2015 Mar 25;10(3):e0117207. doi: 10.1371/journal.pone.0117207. eCollection 2015.

~~

Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library.

Feng J, Weitner M, Shi W, Zhang S, Sullivan D, Zhang Y.

Antibiotics (Basel). 2015 Sep 16;4(3):397-410. doi: 10.3390/antibiotics4030397.

~~

Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection.

Feng J, Shi W, Zhang S, Zhang Y.

Emerg Microbes Infect. 2015 Jun 3;4:e31. doi: 10.1038/emi.2015.31.

~~

An optimized SYBR Green I/PI assay for rapid viability assessment and antibiotic susceptibility testing for Borrelia burgdorferi.

Feng J, Wang T, Zhang S, Shi W, Zhang Y.

PLoS One. 2014 Nov 3;9(11):e111809. doi: 10.1371/journal.pone.0111809. eCollection 2014.

~~

Economic impact of Lyme disease.

Zhang X, Meltzer MI, Peña CA, Hopkins AB, Wroth L, Fix AD.

Emerg Infect Dis. 2006 Apr;12(4):653-60.

Part 2- Human Studies

Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases

Kenneth B. Liegner

Published: 30 May 2019

QUOTE- "Abstract: Three patients, each of whom had required intensive open-ended antimicrobial therapy for control of the symptoms of chronic relapsing neurological Lyme disease and relapsing babesiosis, were able to discontinue treatment and remain clinically well for periods of observation of 6–23 months following the completion of a finite course of treatment solely with disulfiram. One patient relapsed at six months and is being re-treated with disulfiram."

To read the full article click on this link or the pdf below.

https://drive.google.com/file/d/1ap3dgxLUoHfDhcUZPep326CDE2dLHjJI/view

More Human Studies

Precision medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: part 1.

Horowitz RI, Freeman PR.

Int J Gen Med. 2019 Feb 18;12:101-119. doi: 10.2147/IJGM.S193608. eCollection 2019.

~~

Precision Medicine: The Role of the MSIDS Model in Defining, Diagnosing, and Treating Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illness: Part 2.

Horowitz RI, Freeman PR.

Healthcare (Basel). 2018 Nov 5;6(4). pii: E129. doi: 10.3390/healthcare6040129.

Last Updated- December 2019

Lucy Barnes

AfterTheBite@gmail.com